Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.

In sequence, these studies covered a period of up to almost 2 years of treatment with risankizumab (96 weeks, less the follow-up period when the study drug was not administered), during which the clinical efficacy demonstrated an overall trend toward improvement over time.

also in 4,871 other papers